🚨 New in nature (Oct 2025): mRNA vaccines = new immune adjuvants? 💉 Receiving a COVID-19 mRNA vaccine within 100 days of starting immune checkpoint inhibitors (ICIs) nearly doubles overall survival in NSCLC & melanoma patients. Mechanism? IFN-I surge + PD-L1 upregulation =

🌟Excellent table summarizing the essential advances in breast cancer — from molecular profiling to targeted therapies. Clear, comprehensive, and clinically relevant.

🚨Nature Oncology news 🧬 HER2DX brings precision to geriatric HER2+ breast cancer. In the Trans-RESPECT study, this 27-gene assay proved independently prognostic in women aged 70–80. ✨ 74% were low-risk with excellent 10-year OS (85.9%) on trastuzumab ± endocrine therapy —

#FDA has granted traditional approval to tarlatamab-dlle (Imdelltra) for adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed on or after platinum-based chemotherapy. A meaningful step forward for a population long in need of more effective

🚨 FDA Approval Alert – A New Era in Muscle-Invasive Bladder Cancer! The FDA has approved Perioperative Pembrolizumab + Enfortumab Vedotin for cisplatin-ineligible MIBC.

📢A new chapter begins for HER2-mutant lung cancer.

HER2 targeting beyond breast & gastric: Zanidatamab shows a remarkable mOS 18.1 months in metastatic BTC. 🔬 Zanidatamab is expanding across HER2-driven tumors. Already active in breast 🩷 and gastric/GEJ 💛 cancers — now delivering meaningful benefit in biliary tract cancer 💚.

🌟A new day, a new FDA approval — and another reason to smile

🌟These outcomes are hard to ignore. Adjuvant carboplatin delivering such a strong survival benefit in early TNBC could meaningfully change how we treat our patients #SABCS25 OncoDaily

#SABCS25 Insight: SG Falls Short on PFS—Yet Shows an Early OS Promise in HR+/HER2- Disease @oncodailiy

📢SABCS Breakthrough: T-DXd Halves Recurrence Risk in High-Risk HER2-Positive Disease #NEJM #SABCS2025 LARVOL OncoDaily nejm.org/doi/full/10.10…

📢From Doubling PFS to Cutting Recurrence Risk by 30%: The Full Picture of Giredestrant #SABCS2025 OncoDaily LARVOL Mustafa Özdoğan, MD

🌸Here are the Top 10 abstracts that will meaningfully influence real-world oncology:

🚨 SABCS25 Key Takeaway: Alcohol Directly Increases Breast Cancer Risk New data shared at #SABCS25 reinforce a clear message: The more alcohol consumed — especially binge drinking — the higher the breast cancer risk. ✔️ Binge drinking = strongest association, particularly in

📢ASCENT-07 Trial: PFS Missed, OS Promising #SABCS25 OncoDaily LARVOL

📢Less treatment, better outcomes. ctDNA-guided de-escalation in ER+/HER2– metastatic breast cancer shows longer PFS with no chemotherapy. Precision oncology is redefining value. #SABCS2025 #BreastCancer #ctDNA #PrecisionOncology

🚨 BREAKING: The Standard of Care Has Changed!The FDA has approved Niraparib + Abiraterone for BRCA2-mutated mCSPC. With a 54% risk reduction, we are no longer waiting for resistance. Precision medicine is now the front line. @oncodailiy @larvol U.S. FDA #FDA #Oncology #BRCA2

📢FDA approved Destiny Breast 09!!!